The investment objective of the Cell is to seek long term capital growth from an actively managed portfolio of Shariah-compliant securities which may be located in any jurisdiction or in any economic sector provided that such securities are listed securities or securities quoted on a Recognised Stock Exchange. The Investment Manager will seek to provide a consistent return over time in excess of the S&P Developed BMI Shariah Index.
WSF Global Equity USD A
Latest Price NAV
USD
21.74
as of
12/Sep/23
Objective
Performance
3 Yrs Performance
-2.24
5 Yrs Performance
0.40
10 Yrs Performance
4.24
Top Holdings
1.
Roche Holding AG
1.31
%
2.
Carsales.Com Ltd.
1.3
%
3.
ASML Holding N.V.
1.29
%
4.
Tgs-Nopec Geophysical Company ASA
1.28
%
5.
Bristol-Myers Squibb
1.28
%
6.
Novo Nordisk A/S
1.27
%
7.
Biogen Idec Inc.
1.27
%
8.
Pfi Zer Inc.
1.27
%
9.
Coloplast A/S
1.26
%
10.
Constellation Software Inc.
1.26
%
Portfolio Composition
1.
United States
60.83
%
2.
United Kingdom
7.58
%
3.
Others
6.5
%
4.
Australia
5.89
%
5.
Canada
4.94
%
6.
Denmark
3.87
%
7.
Japan
3.2
%
8.
Switzerland
2.52
%
9.
Norway
2.38
%
10.
France
2.29
%
Transaction Information
Annual Charges
Minimum Charge :
N.A
Maximum Charge:
N.A
Actual Charge :
1.5
Initial Charges
Minimum Charge :
N.A
Maximum Charge :
6
Actual Charge :
N.A
Redemption Charges
Minimum Charge :
N.A
Maximum Charge:
N.A
Actual Charge :
N.A
Contact
Company Name:
Cogent Asst Mgmt
Website :
http://www.cogent-assets.com/